Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARK7 | Q99497 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | TTR | P02766 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6323833 | 1.00 | PARK7 (0.41) | PARK7KMT2AALDH1A1MAPTCA1 | |
| SCHEMBL9179440 | 0.75 | PARK7 (0.51) | PARK7KMT2AALDH1A1MAPTCA1 | |
| SCHEMBL6319755 | 0.73 | ALDH1A1 (0.46) | PARK7KMT2AALDH1A1MAPT | |
| SCHEMBL6323847 | 0.73 | ALDH1A1 (0.46) | PARK7KMT2AALDH1A1MAPT | |
| SCHEMBL6317014 | 0.68 | HTT (0.38) | KMT2AALDH1A1MAPT | |
| SCHEMBL6317012 | 0.68 | HTT (0.38) | KMT2AALDH1A1MAPT | |
| SCHEMBL6319581 | 0.68 | CASP1 (0.39) | KMT2AALDH1A1MAPTCA1CA2 | |
| SCHEMBL6317225 | 0.68 | SMN1; SMN2 (0.43) | ALDH1A1MAPTCA1CA2PTPN1 | |
| SCHEMBL6317230 | 0.68 | SMN1; SMN2 (0.43) | ALDH1A1MAPTCA1CA2PTPN1 | |
| SCHEMBL6557476 | 0.67 | ALDH1A1 (0.38) | KMT2AALDH1A1MAPTTTRHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6969729-B2 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S (DK) | 2005-11-29 | — | — | US | claimed |
| US-20030114513-A1 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S | 2003-06-19 | — | — | US | claimed |
| JP-2002531498-A | — | — | 2002-09-24 | — | — | JP | claimed |
| US-20020016354-A1 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S (DK) | 2002-02-07 | — | — | US | claimed |
| EP-1135123-A1 | USE OF ISATIN DERIVATIVES AS ION CHANNEL ACTIVATING AGENTS | NEUROSEARCH A/S (DK) | 2001-09-26 | — | — | EP | claimed |
| WO-2000033834-A1 | USE OF ISATIN DERIVATIVES AS ION CHANNEL ACTIVATING AGENTS | NEUROSEARCH A/S (DK) | 2000-06-15 | — | — | WO | claimed |
| US-6969729-B2 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S (DK) | 2005-11-29 | — | — | US | disclosed |
| US-20030114513-A1 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S | 2003-06-19 | — | — | US | disclosed |
| US-20020016354-A1 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S (DK) | 2002-02-07 | — | — | US | disclosed |
| EP-1135123-A1 | USE OF ISATIN DERIVATIVES AS ION CHANNEL ACTIVATING AGENTS | NEUROSEARCH A/S (DK) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000033834-A1 | USE OF ISATIN DERIVATIVES AS ION CHANNEL ACTIVATING AGENTS | NEUROSEARCH A/S (DK) | 2000-06-15 | — | — | WO | disclosed |
| EP-0432648-B1 | Isatine derivatives, their preparation and use | NEUROSEARCH AS (DK) | 1995-08-02 | — | — | EP | disclosed |
| US-5198461-A | Isatine derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 1993-03-30 | — | — | US | disclosed |
| EP-0432648-A2 | Isatine derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 1991-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114513-A1 | Use of isatin derivatives as ion channel activating agents | KCNN3, KCNJ2, KCND2 | PARK7 548/4885KMT2A 2004/4885ALDH1A1 3865/4885 |
| US-20020016354-A1 | Use of isatin derivatives as ion channel activating agents | KCNN3, KCNJ2, KCND2 | PARK7 493/4885KMT2A 2811/4885ALDH1A1 4102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.